Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932437 · ClinicalTrials.gov registry record · Phase 1
Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
A Phase 1 study of Inhalational Anthrax, sponsored by Elusys Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01932437 is a Phase 1 study of Inhalational Anthrax that has completed, run by Elusys Therapeutics. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01932437, a Phase 1 study of Inhalational Anthrax, has completed, sponsored by Elusys Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ETI-204
Study Locations (1)
Texas
- Covance Clinical Research Unit Inc. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-07-26 |
| Est. Completion | 2014-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932437
The ClinicalTrials.gov registry entry for NCT01932437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elusys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inhalational Anthrax appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01932437 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01932437 about?
NCT01932437 is a clinical study titled "Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers". This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers
What is the current status of trial NCT01932437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-07-26. Estimated completion is 2014-07-03.
What conditions does trial NCT01932437 study?
This clinical trial studies the following conditions: Inhalational Anthrax.
What interventions are being tested in trial NCT01932437?
The interventions under investigation include: Placebo (OTHER), ETI-204 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01932437?
This trial is sponsored by Elusys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01932437 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.